Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cryoport Inc (NQ: CYRX )

8.350 +0.070 (+0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cryoport Inc

< Previous 1 2 3 4 Next >
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
What 4 Analyst Ratings Have To Say About CryoPort
CryoPort (NASDAQ:CYRX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
CryoPort Approves $100M Buyback Program
CryoPort Inc's (NASDAQ: CYRX) Board has authorized a repurchase program. Per the program, CryoPort may repurchase up to $100 million of its outstanding... 
Via Benzinga
CryoPort: Q4 Earnings Insights
CryoPort (NASDAQ:CYRX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
What 5 Analyst Ratings Have To Say About CryoPort
Over the past 3 months, 5 analysts have published their opinion on CryoPort (NASDAQ: 
Via Benzinga
Whither Small Caps After Fed’s Tough Talk?
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... 
Via Talk Markets
CryoPort Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, CryoPort (NASDAQ:CYRX) posted sales of $64.15 million. Earnings were up 31.54%, but CryoPort still reported an overall loss of $9.18 million. 
Via Benzinga
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring... 
Via Talk Markets
Cryoport Stock Shows Market Leadership With Jump To 91 RS Rating
On Monday, Cryoport stock hit a key technical milestone, with its Relative Strength Rating upgraded to 91, a rise from 82 the day before. 
Via Investor's Business Daily
Recap: CryoPort Q2 Earnings
CryoPort (NASDAQ:CYRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings CryoPort missed estimated earnings... 
Via Benzinga
Recap: CryoPort Q3 Earnings
CryoPort (NASDAQ:CYRX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings CryoPort... 
Via Benzinga
CryoPort's Earnings: A Preview
CryoPort (NASDAQ:CYRX) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that CryoPort will... 
Via Benzinga
Small Cap Biotechs Regain Momentum
Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values. 
Via Talk Markets
CryoPort Earnings Perspective: Return On Invested Capital
According to data from Benzinga Pro, during Q1, CryoPort's (NASDAQ:CYRX) reported sales totaled $52.30 million. Despite a 94.85% increase in earnings, the company posted a loss of $13.40 million. 
Via Benzinga
Expert Ratings for CryoPort
Over the past 3 months, 5 analysts have published their opinion on CryoPort (NASDAQ:CYRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Earnings Preview For CryoPort
CryoPort (NASDAQ:CYRX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that CryoPort will... 
Via Benzinga
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
4 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
CryoPort Inc (CYRX) Q3 2021 Earnings Call Transcript
CYRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
3 Under-the-Radar COVID Stocks
Some COVID-19 stocks are pretty famous. But other lesser-known names are flying high, too. 
Via The Motley Fool
Exposures COVID-19
Chief Financial Officer Of Cryoport Trades $3.8M In Company Stock
Robert Stefanovich, Chief Financial Officer at Cryoport (NASDAQ:CYRX), made a large buy and sell of company shares on October 14, according to a new SEC filing. What Happened: A... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Biotech Playbook Revisited As Technicals Weaken
Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
Via Talk Markets
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Return on Capital Employed Overview: CryoPort
After pulling data from Benzinga Pro it seems like during Q2, CryoPort (NASDAQ:CYRX) brought in sales totaling $56.19 million. However, earnings decreased 228.2%, resulting in a... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.